SFOSF (Shanghai Fosun Pharmaceutical (Group) Co) Additional Paid-In Capital: $0 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SFOSF Shanghai Fosun Pharmaceutical (Group) Co Ltd SFOSF
72 GF Score
Price $2.20
GF Value $2.57
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Additional Paid-In Capital?

Shanghai Fosun Pharmaceutical (Group) Co SFOSF 72 Additional Paid-In Capital is $0 Mil as of Jun. 2026. GuruFocus rates SFOSF with a GF Score™ of 72/100 and a GF Value™ of $2.57 (Modestly Undervalued). The stock has 10 warning signs investors should review.


Shanghai Fosun Pharmaceutical (Group) Co's quarterly additional paid-in capital declined from Dec. 2025 ($2,277 Mil) to Mar. 2026 ($0 Mil) but then stayed the same from Mar. 2026 ($0 Mil) to Jun. 2026 ($0 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual additional paid-in capital declined from Dec. 2023 ($2,184 Mil) to Dec. 2024 ($2,139 Mil) but then increased from Dec. 2024 ($2,139 Mil) to Dec. 2025 ($2,277 Mil).

Shanghai Fosun Pharmaceutical (Group) Co Additional Paid-In Capital Related Terms

Shanghai Fosun Pharmaceutical (Group) Co Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Additional Paid-In Capital Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,756.82 2,236.17 2,184.08 2,138.95 2,277.07

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,166.29 0.00 2,277.07 0.00 0.00
SFOSF
72GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd SFOSF
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $0 Mil mean?
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Additional Paid-In Capital of $0 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Additional Paid-In Capital too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Additional Paid-In Capital is $0 Mil. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Additional Paid-In Capital compare to ZTS?
Shanghai Fosun Pharmaceutical (Group) Co's Additional Paid-In Capital of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Additional Paid-In Capital is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.57, compared to a current price of $2.20 — trading 14.4% below its estimated fair value. The current Additional Paid-In Capital is $0 Mil. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Additional Paid-In Capital is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of $2.20 is trading 14.4% below its estimated GF Value™ of $2.57. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for SFOSF:

  • Additional Paid-In Capital: $0 Mil
  • GF Value™: $2.57 vs. price of $2.20 (14.4% below fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
72GF Score

Get the complete analysis for SFOSF

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.20
Price
$2.57
GF Value